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INTRODUCTION
It has been well documented that reaching beyond
MEDLINE into a diversity of databases enhances
search results [1–3], but a chronic question in
comprehensive and systematic searching is how far,
and where, to search [4]. When published in business
or economics sources, articles focusing on cost
outcomes of health and health policy interventions
may not be indexed in the biomedical databases that
are traditionally consulted for clinical systematic
reviews [5]. The goal of this dual case study is to
explore and document the significance of non-health
sources, specifically databases that index economic
research, in comprehensive searching for two system-
atic reviews of pharmaceutical policy interventions.
Due to ethical and logistical constraints, as well as
lack of political will, controlled experimental studies
of health policy interventions are rare [6]. The classic
systematic review hierarchy of evidence may not
apply to many policy reviews, as interventions of this
type often can only be studied by using ‘‘natural
experiments’’ and observational study designs [7].
Thus, systematic reviews of health policy interven-
tions present methodological challenges to the inves-
tigators that are important for the librarian to be
aware of—for example, the decision as to exactly
which study designs or types of data are acceptable.
Once the inclusion and exclusion criteria are clearly
defined, the librarian must determine which sources
are likely to be most productive. Search strategies for
health policy reviews necessarily require a broader
approach than that used in a classic clinical systematic
review search, as sources such as the Cochrane
Central Register of Controlled Trials (CENTRAL)
and tools such as search filters for identifying
randomized controlled trials will typically not be as
fruitful for policy reviews as they are for reviews of
therapeutic interventions. In an ideal world, one
would always exhaustively search any source of
possible relevance. However, when balancing time
and resource constraints, it is useful for librarians to
be aware of which sources are likely to provide the
highest return on their investment.
METHODS
This dual case study was based on searches conduct-
ed by a librarian embedded in an interdisciplinary
health policy research centre located at a large
Canadian university. In both systematic reviews, the
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intention was to examine clinical and economic
outcomes of pharmaceutical policy interventions.
Both literature searches were done in several data-
bases, including a mixture of core biomedical data-
bases and others thought to yield relevant clinical
and/or economic results. While most databases are
common to both searches, some more ‘‘niche’’ sources
were specifically selected for one or the other. As is
common for systematic review searching, both search
strategies also included citation snowballing, expert
referral, gray literature searching, and some degree of
hand-searching in core journals.
The search question in review #1 was: What are the
clinical or economic outcomes (including health
services use) of implementing either a reference
pricing scheme or tiered formulary for prescription
medications? Acceptable study designs included:
randomized controlled trials, before-and-after or
pre/post studies with nonrandomized comparison
groups, interrupted time series analyses with or
without comparison groups, and pre/post studies
without a comparison group [8].
The investigators searched in a fairly standard suite
of biomedical databases (CINAHL, Evidence Based
Medicine Reviews, EMBASE, International Pharma-
ceutical Abstracts, and MEDLINE) as well as the
business database ABI/Inform, the economics data-
base EconLit, the general database Web of Science,
ProQuest’s Digital Dissertations & Theses (PQDT)
database, and the Public Affairs Information Service
databases (PAIS International and PAIS Archive). In
addition to these major subscription databases and
indexes, we searched a host of gray literature sources
and online search tools.
The search question in review #2 was: What are the
clinical or economic impacts (including health servic-
es use) of any form of direct-to-consumer advertising
(DTCA) of prescription drugs? Acceptable study
designs for this review were randomized controlled
trials including cluster randomization trials, con-
trolled before-after studies with contemporaneous or
historic control, nested or non-nested case-control
studies, comparative cross-sectional studies, and
interrupted time series analyses.
We searched in the same suite of biomedical
databases detailed above and all the same additional
subscription databases with two exceptions: ABI/
Inform was abandoned as unlikely to contribute
usable, unique studies after pilot searches on the topic,
and Worldwide Political Science Abstracts was added,
as the investigators wanted to attempt to capture
relevant studies published abroad in law or political
sciences sources. The lists of Internet and gray
literature sources searched in the two reviews differed
slightly as well; for example, the DTCA review
searched in the Drug Promotion Database (DPD),
which was selected specifically for applicability to this
second review but not seen as relevant for the first.
All citations retrieved for the reviews were tagged
with their sources of origin (e.g., database name or
other method of discovery). Absolute number and
percentage of relevant citations were tracked after the
initial title-level review of citations, after the full-text
review, and after the reviewers’ final assessment of the
articles meeting criteria to be included in the review.
Citation sources for each review were analyzed for
number of results from the source that were included
in the review, number of unique results (found in no
other source) included in the review, and ‘‘missed’’
results—in other words, citations that turned up in
another search and ‘‘should’’ have been duplicated in
that database search as well. Table 1 illustrates the
number of citations, as well as the number of unique
citations from no other source, for each database that
furnished studies included in the two reviews.
RESULTS
Review #1: the impact of reference pricing and
tiered formularies
Results indicate that MEDLINE and EMBASE, while
highest in number of relevant citations, provided no
unique results appropriate for inclusion in the final
review. Non-biomedical sources, such as economic
and business databases, on the other hand, garnered
relevant results not indexed in biomedical databases.
Citation snowballing offered more unique results than
any database. For this review, neither PAIS nor our
extensive web-based gray literature searching added
results that could be included.
Of the twelve articles included in the reference
pricing and tiered formularies review, only three were
unique to a particular database. Those databases were
EconLit, ABI/Inform, and PQDT. Five additional
articles were uniquely identified through citation
Table 1
Included and unique studies, by source*
ABI/
Inform CINAHL
Evidence
Based
Medicine
Reviews EconLit EMBASE
International
Pharmaceutical
Abstracts MEDLINE
ProQuest’s
Digital
Dissertations
& Theses
Web of
Science Other*
Review 1: included 1 1 1 1 4 3 7 1 1 5
Review 1: unique 1 — — 1 — — — 1 — 5
Review 2: included n/a 4 — 2 7 7 8 8 11 9
Review 2: unique n/a — — — — — 1 6 2 3
* Worldwide Political Science Abstracts and Public Affairs Information Service were also searched for review #2 but yielded no relevant studies.
Other sources for review 1 means citation snowballing.
Other sources for review 2 means citation snowballing, Cochrane Central Register of Controlled Trials, Drug Promotion Database, and OAIster.
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snowballing. The remaining four articles appeared in
multiple data sources.
Review #2: the impact of direct-to-consumer
advertising of prescription drugs
Similar to review #1 described above, core biomed-
ical databases yielded the largest number of results,
but few unique items. Interdisciplinary databases
such as Web of Science and PQDT did provide unique
citations. In this review, EconLit was less fruitful and
ABI/Inform was not searched. Neither political
science database (PAIS or WPS) garnered any
citations appropriate for inclusion in the review.
However, gray literature sources such as the OAISter
meta-repository search and DPD provided a unique
result, as did citation searching.
Of the twenty-six articles included in the DTCA
review, nine were unique to a particular database,
and of those nine, six were found in PQDT. Two were
in Web of Science and one in MEDLINE. The
remaining three were found via OAIster, DPD, and
citation searching.
DISCUSSION
Economic outcomes are increasingly evaluated along-
side clinical outcomes in health policy research and
reviews [9]. Including both types of outcomes may
increase policy relevance of the research, as decision
makers struggle with questions not only of clinical
efficacy, but also real life effectiveness and cost
efficiency of interventions [10].
Large biomedical databases such as MEDLINE and
EMBASE, which are common first sources to consult
in a health-related review, are certainly inadequate as
sole sources. Further, as demonstrated in this study,
they may not be as essential in identifying unique
articles for systematic literature searching as smaller,
niche databases in tangential fields, due to the large
amount of duplication of content among the large,
comprehensive databases. As has been the case in
other studies, citation snowballing is affirmed here as
a critical element of the systematic review search
process. Gray literature search tools are emerging as
highly useful in some searches as well, particularly
topics such as DTCA, which are relatively new
interventions with strong appeal to a broad, interdis-
ciplinary community of researchers.
While this study focused on two reviews of
pharmaceutical policy interventions, cost effective-
ness and resource-related outcomes of health tech-
nologies, methods of organizing health care, and
population health interventions are of broad concern;
thus, the results of this study will likely be applicable
to many health policy topics. Investigators seeking to
complete systematic reviews of pharmaceutical and
other health policy interventions should strongly
consider including non-biomedical databases, partic-
ularly economic and interdisciplinary databases, in
their search strategies, along with citation snowball-
ing and gray literature searching. When considering
wise use of scarce available resources, it may be a
better investment to look in ‘‘niche’’ databases or gray
literature sources, rather than multiple core biomed-
ical databases with large portions of overlap.
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